Kieran Murphy is President and Chief Executive Officer of GE Healthcare Life Sciences, a $3.7 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for therapy selection and treatment monitoring in patient care. Kieran was appointed CEO in May 2013, following a strategic decision to combine the product and technical capabilities of two former GE Healthcare units, Life Sciences and Medical Diagnostics.

Kieran joined GE Healthcare in 2008 from Whatman plc, a $230 million global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Kieran has over twenty years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc.

Kieran earned his bachelor’s degree in 1984 from University College, Dublin. He subsequently graduated from the University of Manchester Institute of Science and Technology with a master’s degree in Marketing.

Ann is Senior Director of New Ventures at Johnson & Johnson Innovation, London.

Her role involves seeking out the best science and technology available to deliver next generation therapies for serious diseases. Once identified, Ann works with J&J and the partner organisations to put together the right collaboration framework to transform those innovations into products.

Ann has extensive experience in the Pharmaceutical Industry; prior to joining J&J she was Senior Director of Business development with UCB Pharma where she was responsible for Business Development activities to support both the Immunology and CNS early phase portfolio. Ann has also spent 13 years in various drug development roles at GSK. During her time there she worked in preclinical development supporting the progression of multiple programmes in many therapeutic areas through the drug development process. She was also part of the GSK Neurology Centre of Excellence providing preclinical input for the early phase development portfolio. Ann is a scientist by training and holds a PhD in Biochemical Toxicology from the University of Surrey.

Dr Eliot Forster joined Immunocore as Chief Executive Officer in January 2015. He has almost 25 years of experience in the pharmaceutical and biotechnology industry. Dr Forster previously served as Chief Executive Officer of Creabilis since 2010 and prior to that role was Chief Executive Officer of US biotechnology company, Solace Pharmaceuticals Inc. His other previous roles include Head of EU Development and Operations for the EU and Asia at Pfizer, where he was responsible for drug development activities across multiple geographies and brought several drugs to market, and Clinical Research Manager at GlaxoSmithKline. Dr Forster is currently Chairman of the MedCity project that aims to grow a world-leading life sciences cluster in the south east of England. He holds a PhD in neurophysiology from Liverpool University and an MBA from Henley Management College.

Nick is Director of Commercial Development at the Oxford Academic Health Science Network where he is responsible for working with industry, the NHS and academic partners to commercialise new innovations in the digital, medtech, diagnostics, and pharmaceutical sectors. His focus is on building partnerships to support the adoption of new technologies into the NHS.

Nick has over 25 years’ experience in commercial and business development in the life sciences sector. He has an MA in Natural Sciences and a PhD in the Philosophy of Science from Cambridge University. After leaving university he set up a vaccine company before working in blue chip life science companies such as PowderJect Pharmaceuticals where he was VP Corporate Affairs, responsible for strategy and government affairs. He has also had extensive experience as a consultant, specialising in strategy and corporate finance support working with public and private sector clients. From 2006-11 he was a special industry consultant to the BioIndustry Association working on pharmaceutical pricing and uptake. He played a leading role in representing the life sciences industry position on the drafting and passage of the Biotechnology Patents Directive through the European Parliament in the 1990s. He was awarded the MBE for services to biotechnology in 2001.

Alan is a well-known Korean entrepreneur with over 15 years of success in the startup industry. His first company, ranked as the number 8 Fastest Growing Technology Company by Deloitte Technology Fast 500, sold for $30 million to South Korea’s #1 communications company. His current company, BeNative, is an online education platform for learning English and Mandarin Chinese, and is used by customers in China, Japan, South Korea, and Taiwan. BeNative is also developing a free service called "CashEnglish" that will soon be launched globally. Outside of business, Alan has co-founded a non-profit that helps North Korean refugees assimilate into South Korean society. He is also the director and co-founder of Mechanism Angel Fund. Combining his thirst for knowledge, his expertise in technology, and his talent in connecting people and projects, Alan is perfectly poised to guide entrepreneurs in today’s global business world. Alan received his engineering degree from South Korea’s prestigious SNU, and is currently working on a PhD in Big Data Analytics from Korea's aSSIST and MBA from China's CKGSB.

Ian Tomlinson has over 25 years of experience in the lifesciences sector from academic research to biotech startup to big pharma. He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK.

He is currently Chairman of the Board at the Stevenage Bioscience Catalyst, UK's first open innovation biomedical campus. He is also Chairman of the Investment Committee for Apollo Therapeutics, a £40 million fund dedicated to turning academic biotechnologies into novel medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.

Dr Tomlinson graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.

Alan Barrell has spent almost 30 years in senior executive positions in technology based industries and has become one of Cambridge's most articulate promoters of entrepreneurship. He was a founder shareholder in Library House Ltd, and is now Entrepreneur in Residence at the University's Centre for Entrepreneurial Learning and Visiting Professor of Enterprise at the University of Bedfordshire School of Graduate Business Studies. He is also Distinguished Guest Professor at Xiamen University, Visiting Professor at Shanghai College of Science and Technology and at the Fujian International School of Economics and Business, Fuzhou and Guanzi University, all in China. He has taught at Tsinghua University Beijing, Fudan University in Shanghai and Minjiang University, Fuzhou City. He acts as Consultant to the China Public Practicing Base for Entrepreneurs. His interest in China, its history, people and culture has become a major feature of his life and work. Other appointments include Senior Enterprise Fellow, University of Essex, International Fellow, Anglia Ruskin University Cambridge, and International Research Fellow, Laurea University of Applied Sciences in Helsinki.

He has been Chairman of Health Enterprise East Ltd, an organisation seeking to exploit innovative inventions, processes and procedures in the National Health Service within the Eastern Region since it was set up five years ago. Following a scientific training and six years working in clinical laboratory medicine in the NHS at the start of his career, he worked around the world with Baxter Healthcare and was its UK Chief Executive for six years. Subsequently, he joined Domino Printing Sciences plc as Managing Director. Domino became a public company and now has a market capitalization of more than Euros half a billion. Following six years with Domino ,he joined Willett International Group, an industrial electronics company, and was its CEO, building its global business into a major success.

He was then instrumental in launching the Cambridge Gateway Fund, a 70 millions Euros fund, to support early stage technology businesses in the region and became its Managing Partner, and has been involved with a number of charities including the Papworth Trust, the Royal Society of Arts, the Centre for Tomorrow's Company and The Prince's Trust. He is currently International Advisor to Youth Business China

He has also chaired the Cambridge Enterprise Conference and works closely with a number of Science Parks and Innovation Centres in Cambridge, elsewhere in the UK and overseas. He received The Queen's Award for Enterprise Promotion in 2006.

Most recently, Alan has become Chairman of Eagle Genomics Ltd, and Pneumacare Ltd., and a Director of Probe Scientific Ltd. All are entrepreneurial early stage Life Science Companies. He is a Director of two Chinese Companies – Golden Bough Intellectual property Company and Oriental Investments Ltd.

In October 2009 The Regional Strategic Health Authority for the East of England appointed Alan Chairman of the NHS Innovation Council and in November he accepted an invitation to act as Chairman of the Trustee Board of NACUE - an organization which grew in its first year to have 40,000 members and embrace 80 University Enterprise Associations. He is also advisor to Start Up Generation an international organisation supporting start up companies around the world.

Alan is a member of Cambridge Angels and Sophia Business Angels (France) and advises numerous early stage companies internationally.

During 2010 Alan has devoted increasing time to supporting Innovation in Health care and was appointed in October 2009 Chairman of the NHS East of England innovation Council. In August 2010, Alan was elected Entrepreneur in Residence, Walter G. Booth School of Engineering Practice, McMaster University, Hamilton Ontario and was re-appointed in March 2013. Alan has been doing extensive work on cross border investing and technology transfer involving UK and Canada, supported by Industry Canada, the Government of Ontario and The Canadian High Commission in London.

On February 1st, on behalf of the President of Finland, Ms. Tarja Hanonen, Alan was conferred the honor of Knight First Class – Order of the White Rose of Finland by the Finnish Ambassador to UK – Mr. Pekka” in recognition of his services to the development of Creative and Innovative University Education in Finland – largely through his activities at Laurea University of Applied Sciences in Helsinki.

During a working visit in February 2011 to Sendai in Japan, Alan was appointed Distinguished Guest Professor at Tohoku Fukushi University, by the President, Professor Koki Hagino

In 2012 Alan Barrell, worked as a founder director of the International Commercialization Alliance which seeks to encourage best practices in turning research into good products.

During 2012 work on the development of new approaches to entrepreneurial education and new pedagogical methods to develop effective entrepreneurs has proceeded through more collaborations between Universities and companies in UK, Finland, USA and China and Alan has been significantly involved. This includes work on the Advisory Board of the Postgraduate Diploma in Entrepreneurship at University of Cambridge. Extensive work has been undertaken in Entrepreneurial Education in Latvia and other Baltic States. In 2013 further educational development work with University of Hong Kong and Hong Kong Polytechnic University as well as Singapore Institute of Management has been undertaken.

In August 2013 the book “Show Me The Money – How to raise the cash to get your business off the ground” co-authored by Alan Barrell, David Gill and Martin Rigby was launched and the first printing was sold out inn six months. Now reprinted and selling worldwide.

Lily is the Director of Business Operations and Project Management at the London Innovation Centre. In this role she has responsibility for coordinating the operational management of the Innovation Centre including transaction and project reviews as well as day-to-day processes.

In addition she is also responsible for planning and executing a number of key infrastructure projects for a variety of internal stakeholders and external business partners while working synergistically with her colleagues in the other centres.

She graduated summa cum laude with Bachelor of Arts degree in psychology from William Paterson University in New Jersey and completed her MBA at the Judge Business School, University of Cambridge.

Professor Yu Xiong is the Chair of Technology and Operations Management in Newcastle Business School. He is the only UK-based committee member of the prestigious All China Youth Federation, and the only UK based award holder of high-profile May 4th Medal presented by provincial Chinese government.
Prior to his current appointment, he was a Senior Lecturer/Associate Director for Enterprise, Engagement and External Relations of Norwich Business School and a Lecturer/director of China Management Research Institute in Queen's University Management School, Belfast. His research focuses on sustainable manufacturing and supply chain strategies, in the international environment. He is advising the Department of Business, Innovation and Skills (BIS) in the UK about innovation collaboration with China, via his role as a core member of the China UK Innovation Expert Group run by the UK department of Business, Innovation and Skills. In China he was appointed to be a member of the International Affairs Committee, Chinese People's Political Consultative Conference in Chongqing (Chinese provincial parliament). He delivered keynote speeches in national events organized by Department of BIS, the UK Parliament, the UK Intellectual Property Office, British Council, China Britain Business Council, China Ministry for Science and Technology etc.
Prof. Xiong has extensive industry collaborations, he is directors to several influential companies, as company director of ADAPT Commercial(http://www.adaptlowcarbongroup.co.uk), he helped the company to forge a 100 million venture capital fund; as company director to Cocoon Network Ltd(http://www.cocoon-networks.com/), he helped establish the largest incubator in the European Union, in Liverpool street of central London; as a company director and chief advisor to SinoFortone(http://www.sinofortone.com/ , he developed the recently announced 5.5 billion GBP investment to the UK; as a board member of ELI Holding Ltd(http://www.eliholdings.com/ ), he helped the company to develop several influential international merge and acquisitions. Professor Xiong also has extensive collaborations with many other big industry players including Unilever, Bombardier, SAP, DOW Chemical, National Heath Service etc.
Prof Xiong’s researches have been published in international leading/excellence level journals in his research areas, including European Journal of Operational Research(ABS 4*), International Journal of Production Research(ABS 3*), International Journal of Production Economics(ABS 3*), Journal of Operational Research Society(ABS 3*), etc. As principal investigator, He is constantly getting funding from national funding bodies including the British Academy, British Council, Technology Strategy Board, etc. He has been lead guest editors to many international excellence journals, including International Journal of Technology Management(ABS 2*), Technovation(ABS 3*) etc.

Professor Xiong is an active member of many academic networks. He is the founder/Chair/co-Chair of the following well known activities: China Innovation and Development Association, the China UK Entrepreneurship Competition, and the International Forum on Innovation Oriented Economics. He is also a Chartered Engineer in the UK. Because of his academic contribution to the link between China and UK, he was invited by the London Olympic Organising Committee to be one of only two Chinese academics in the world as Olympic Torch Bearer 2012. He is a visiting Professor and Director of the Institute of Science and Technology Innovation Policy of Zhejiang University(3rd in China, QS World University Rank: 144, ARWU Rank: 151-200), and visiting Professor of Chongqing University(28th in Chinese Ranking), and Central South University(15th in Chinese Ranking) in China. In 2015, Professor Xiong became the only UK scholar who received the prestigious May 4th Medal from Chongqing Government in China, to recognize the research and practical impact created by him in both China and the UK.

Chas is Professor of Translational Medicine in the Nuffield Department of Clinical Medicine and Associate Member of the Department of Pharmacology at the University of Oxford. He is also a Visiting Professor in Neuroscience and Mental Health at Imperial College, London. Chas is an invited expert on several government and charitable research funding bodies, and an advisor for many academic, biotech and pharma drug discovery programmes.

Prior to coming back to Oxford, Chas was Vice President and Head of Biology at GlaxoSmithKline. He was involved in the identification of more than 40 clinical candidates for many gastro-intestinal, inflammatory and neuro-psychiatric diseases. More than 20 of these molecules progressed into patient studies and more than five of these delivered successful “Proof of Concept” data and hence progressed into late stage development. He was involved in the launch and development of the first treatment for Irritable Bowel Syndrome (Alosetron) and was the first to show that neurokinin NK1 antagonists are anti-emetic in preclinical and clinical studies.
His current interests are i) using X ray structures of novel human proteins to generate small molecule inhibitors, screening in human cells to identify novel targets for drug discovery, and then developing clinical candidates for evaluation in patients, pre-competitively ii) focussing on epigenetic and genetically identified proteins, because these are likely to represent better targets for drug discovery, for many cancer, inflammatory, metabolic and neuro-psychiatric diseases iii) working with colleagues in Oxford to build major programmes in rare diseases and  in Alzheimers Disease, and creating a “BioEscalator” for the rapid translation of SGC science and iv) building stronger links with local hospitals, patient groups, regulatory agencies, private investors, CROs, biotechs and large pharma companies, to create a new, more efficient ecosystem for pioneer drug discovery.

Chas believes the SGC has become a leader in human protein structural biology and epigenetics chemical biology, and is arguably one of the most successful open innovation, public – private partnerships  in the world. Furthermore, with the many recent local developments (Target Discovery Institute, Kennedy Institute), he believes Oxford is emerging as one of the major academic drug discovery centres in Europe.
He has given over 300 invited lectures.  In 2012 he was voted one of the “top innovators in the industry”.

As an entrepreneur, Simon has been involved in the formation of 16 companies to date – including AIM-listed investment vehicle IPSO Ventures PLC.

In recent years he has been focussing on the opportunities offered by China-UK interactions, first setting up a Chinese subsidiary in Wuhan, Hubei Province for a UK bioinformatics company in order to learn first hand how to engage with China, and then establishing The Sino-UK Fund to invest in UK and European life science, med tech and cleantech companies whose products have not yet been exploited to their full potential in China.

The Sino-UK Fund is formed as a co-GP partnership between the UK origination team and a major private equity house in Beijing and it is this combined force that allows the firm to access projects in the UK and then to introduce them successfully to China, using Chinese capital. The Fund takes all its investments to China for development and to access the PRC market.

Though Simon didn’t know it when he started engaging with China, Simon’s family has been connected with China for over 100 years.

Tom holds a PhD in Experimental Oncology and has served in a variety of research, technology development and commercial roles. He has a proven track record of creating value in highly successful start-up companies applying genome-based technologies and contract services for fundamental research, clinical, and drug discovery purposes. He has also led large infrastructure programs in genomics and animal model genetics, serving as a Director at the Medical Research Council (Oxford, UK). He trained at the University of Cambridge and MRC Lab for Molecular Biology (Cambridge, UK), and the University of Wisconsin Medical School, (Madison, USA).

Tom founded Congenica - an international leader in providing clinical data solutions for genetic diagnosis. Congenica is a UK company founded on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories. Congenica translated this research into the gold standard clinical genomic analytics platform, Sapientia, providing integration of human DNA sequences with deep clinical phenotype enabling clinicians to provide actionable interpretation of genetic disease for patients.

Martino is the first CEO of the Stevenage Bioscience Catalyst an ambitious concept to develop an Incubator and Accelerator, followed by a world class Science Park for the Life Sciences sector. Martino has a PhD in Biochemistry from Cardiff University and spent 4 years at Baylor College of Medicine, Houston, TX in Cardiovascular research. Martino joined Amersham International in 1991 and subsequently went on to manage the R&D Technology Transfer Group, based in Cardiff and developing high throughput screening technologies for the Pharmaceutical sector. Following the merger of Amersham with Pharmacia Biotech, Martino became the Science Director for the Cardiff site, Martino then became a Business Manager for Manchester Biotech Ltd. and subsequently Manchester Innovation Ltd. in June 1999. When the Universities of Manchester and UMIST merged, he became Managing Director of UMIC and MICL and was a Board member of UKBI. Martino was also acting Chairman for a start-up company, sri Forensics Ltd (2011-2014) and has previously been on the Board of Cartesian Technologies , BIONOW Steering Committee and was also a non -executive Director for Queen Mary Bioenterprise Ltd (2009-Aug 2010).. Martino has recently been a Board member of the Hertfordshire LEP. Most recently, Martino has been on the Trust Board for the North Herts Studio Schools (Stevenage, Letchworth and Thomas Alleyne Schools) and on the Local Governing Body for the Da Vinci Studio School Stevenage. Martino has also been appointed to the Life Science Wales Hub Board as a Non –Executive) and was recently therecipient of a Herts Chamber of Commerce award for “outstanding contribution to Herts Business “ (May 2014). Martino is also on the assessment panels for CRACK-IT (NC3Rs) and TSB (now Innovate UK) Biomedical Catalyst Funding respectively.

Candace Johnson is a global infrastructure, network and innovation expert and entrepreneur. She is co-initiator of SES/ASTRA for which she was named an Officer of the Luxembourg Oak Leaf Crown and architect of SES Global, one of the world’s largest satellite systems for which she was named Commander of the Luxembourg Order of Merit. She is also founding President of Europe Online Investments S.A., the world’s first internet-based online service and satellite broadband network, and founder of Loral Cyberstar-Teleport Europe, Europe’s first independent private trans-border satellite communications network for which she was named an Officer of the German Federal Order of Merit. Ms. Johnson has recently co-founded Oceania Women’s Network Satellite (OWNSAT). OWNSAT has become a founding investor in the Pacific Satellite System based in Singapore, where Ms. Johnson is also a Member of the Board. Ms. Johnson is also founding President of the VATM, the Association of Private Telecom Operators in Germany and founding President of the Global Telecom Women’s Network (GTWN). She has continued to be a long-time Member of the Board of Directors of all of these companies and organizations at various times throughout the years.

Ms. Johnson is also President of Johnson Paradigm Ventures (JPV) which is a principal founding shareholder with AXA, Caisse des Depots, Bayerische Landesbank, and the SPEF of Sophia Euro Lab, Europe’s first trans-border early-stage investment company based in Sophia Antipolis. JPV is also a principal founding shareholder in London-based Ariadne Capital, “Architecting Europe.net”, one of the earliest supporters and promoters of Skype, the global VoIP phenomenon. Ms. Johnson has served as Founding Member of the Boards of both companies.

In her personal capacity, Ms. Johnson is a Member of the Supervisory Boards of Garage Canada, Iris Capital (Europe) and was a founding member of Inovent (Turkey). Ms. Johnson is founding Member and was President of the Board of the Sophia Business Angels in Sophia Antipolis, France from 2006 – 2008 as well as founding president of three multi-million Euro investment vehicles, Succès Europe, Croissance Europe and Innovation Europe, together with Meeschaert Gestion Prive. Ms. Johnson is also Founding Member of the Cologne Business Angels, Galata Business Angels and Advisory Board of the Luxembourg Business Angels Network. Ms. Johnson was a minority owner of FMN, a German telephone manufacturing company, and a member of their Supervisory Council from 1993 - 2008. She was also a minority owner of Alpha Com, a wireless data manufacturing company.

Through her global investing activity, Ms. Johnson has widened her scope of expertise to include CleanTech and MedTech and has been actively involved in financing such companies as Nheolis, a unique home-turbine energy concept company, and CertiNergy, France’s first B2B2C energy-credit trading company as well as Quotient Diagnostic and AboDiag, life-sciences technology and services companies. In 2006, she created the Festival of the Fourth Dimension, the world’s first festival of the Arts, Technology, and Sciences, which has since become a major French government global initiative for Industrial Innovation and Creativity (Pole ICI) of which she became the 1st Vice President.

Ms. Johnson is a Non –Executive Director of SES-ESL, a publicly quoted corporation on the French Stock Exchange. She has also recently been elected as President of EBAN, the European Business Angel and Early-Stage Investment Network. Ms. Johnson is also the Co-Founder of the Global Board Ready Women initiative.

Ms. Johnson is also a member of the Advisory Board of numerous European and US ventures as well as being a Member of the Board of Governors of EDHEC, France’s largest business school, Sabanci University in Istanbul Turkey, and the International Board of the Hong Kong Polytechnic University as well as being a Senior Enterprise Fellow for the University of Essex/LEEDS Program of the OECD. Recently, she has joined the Board of Advisors for the Techno Parks of the King Abdulaziz City for Science and Technology in Saudi Arabia (KACST). Ms. Johnson is a well-known speaker on innovation and entrepreneurship for such companies as Alcatel-Lucent, Qatar Telecom, IBM, Hewlett Packard, etc. and has been a featured speaker at the Cambridge University Center for Entrepreneurial Learning and the OECD International Entrepreneurship Forums in Shanghai, Riga, and Cape Town.

Ms. Johnson was also Vice President Worldwide of Iridium and brought it into the GSM MoU, the ITU and ETSI as well as obtaining its global frequencies and country codes. She was Director of Marketing for the German manufacturing company FuBa and globalized its manufacturing and commercial activities.

Ms. Johnson has been featured in articles in Time Magazine, the Financial Times, the Economist, Le Monde, WirtschaftsWoche, Manager Magazin, Les Echos, and the International Herald Tribune to name a few. She has been decorated as Commander of the Luxembourg Order of Merit and Officer of the Couronne de la Chene as well as Officer of the Bundesverdienst Kreuz 1. Klasse (FRG) for her work in de-regulation, innovation, privatization, and globalization and the specific projects named above. Further, Ms. Johnson is the second recipient ever of the UN-sponsored World Teleport Associations’ “Founders Award”. Ms. Johnson has also received the “Lifetime Achievement Award” along with Vinton Cerf and Tim Berners Lee from the World Communication Awards, the prestigious global telecoms organization in 2002. Ms. Johnson has also received the Lifetime Achievement Award from The International Alliance of Women in 2012. Ms. Johnson holds Masters Degrees with Honors from the Sorbonne and Stanford Universities, a Bachelors Degree from Vassar College and her high-school degree from Punahou, Honolulu, Hawaii.

Aimie Chapple leads the Accenture health practice in the United Kingdom. Ms Chapple oversees numerous UK based client initiatives and services related to health management, medical imaging, electronic health, and primary and secondary care organisations. Ms Chapple is also responsible for Accenture’s UK health strategy, growth initiatives and market capabilities.

Ms Chapple joined Accenture in 1992 and has a wealth of client and industry experience, particularly in the areas of business change and organisational effectiveness. She has held leadership roles in Accenture’s Human Capital Strategy team, in the Talent & Organisational Performance team and most recently led Accenture Management Consulting in the UK and Ireland from 2010 to 2013. In her current role as Client Innovation Lead, she leads Accenture’s UK and Ireland innovation agenda, working with a wide variety of clients.

Ms Chapple grew up mostly in the US, spent a year studying at the University of Sussex, and graduated from Smith College, Massachusetts with a Bachelor of Arts in social psychology. She has been living with her husband and two daughters in London since 1997.

CEO of AlgoDynamix

Jeremy is CEO of AlgoDynamix, a software risk analytics company focusing on (financially) disruptive events. The software is used by major institutions in both UK and international markets. His previous roles include data analyst (analytics, statistics and user profiling) at a payment processing company and CTO at a telecommunication network infrastructure company. Jeremy co-founded several other companies including OptiSynx (technology acquired) and Cambridge Frequency Standards Ltd. He has an undergraduate and two post graduate degrees in Engineering, including an Engineering PhD from the University of Cambridge (laser physics/quantum mechanics). His interests are in high tech & Interdisciplinary entrepreneurship, data sciences and algorithms.

David Klimczak has been involved in the electric power industry for 8 years. He has managed to build a successful career all while continuing his studies. Dr. Klimczak began his career as a Junior Power Trader and worked his way up to CEO in a relatively short time. He is currently a member of the Governing Board of the Association of Energy Traders in Poland.

For more than two years, Dr. Klimczak specialized in proprietary trading on European power market at German Metro Group. During this time, he received a Bachelor's Degree in International Relations from Nicolaus Copernicus Univerisity. Dr. Klimczak has numerous broker licenses e.g. European Energy Exchange, Energy Exchange Austria, EUREX Exchange and Commodity Broker. In 2012, he joined one of the leading Polish electric utilities, ‘Enea’ and took on the responsibility of natural gas trading, origination and proprietary trading on the German power market. In 2015, he became Director of Prorietary Trading Department. In March 2016, he was appointed CEO of Enea Trading. Dr. Klimczak is now responsible for coal trading, finance, innovation, and development strategies for the European Commodity Market. He has recently completed his Studies at the Technology University in Poznan with a Doctorate of Economic Science.

Additionally, in August 2016, Dr. Klimczak was appointed to the position of CEO at Enea Wytwarzanie. The company generates power and heat to homes all across Poland. It currently produces almost 8% of all the electricity distributed in the country and employs more than 2,500 people nationwide.

Professor Martini is a registered practicing Industrial Pharmacist and a Fellow of the Royal Pharmaceutical Society. Professor Martini is the Roche Innovation and Outreach Lead based in the UK and divides his time between Roche Pharmaceuticals and King’s College London as a Visiting Professor in Pharmaceutical Innovation, after having held the Chair in Pharmaceutical Innovation at King’s for 5 years. Prior to that Professor Martini spent over 17 years working at GlaxoSmithKline Pharmaceuticals working in a variety of Commercial and Innovative roles.

James is the CEO and co-founder of Open Utility, an innovative energy technology company with a mission to democratise energy. In 2015 they partnered with green energy supplier Good Energy to launch Piclo, the UK’s first online marketplace for buying and selling renewable electricity. Since the company’s inception in 2013, James and his co-founders have grown the team to 7 and secured over £1M in funding, including a £310K grant from the Department of Energy and Climate Change and private investment from Ian Marchant, former CEO of SSE. Open Utility won Startup of theYear award at European Utility Week and is one of Bloomberg’s Business Innovators 2016.

James leads our policy and markets work, informing government policy and thinking across the business and the investor community on transforming markets. James also leads our innovation business area, working with governments and corporates to commercialise new low carbon technologies. Prior to joining the Carbon Trust, James worked for management consultants McKinsey & Company. James has a PhD in Nanotechnology from the University of Cambridge and a first class degree in Materials Science from the University of Oxford.

After several experiences gained in cosmetics and fashion industry, Karolina Korth started her health industry related professional career at Siemens in Germany and USA assuming several positions in marketing, sales and strategy departments. In 2015 she took over the role of Business Development Manager at Roche Diabetes Care being responsible for Business Development of Emminens, a Roche company delivering personalized chronic care solutions.

She has a background in psychology and business management and is a true enthusiast of persuasive technology and digital health. In her free time you can find her in the best coffee places in the European cities or at the airport on her way to some places out of the beaten track.

Lisa Melton is Senior News Editor for Nature Biotechnology. Lisa obtained her PhD in Gut Immunology from Buenos Aires University, worked in the lab at the National Institutes of Medical Research in Mill Hill before switching to the more gregarious world of science communication. She has written for the Economist, the New Scientist, Scientific American and Times, and is a guest lecturer in Science Communication at the University of West England. Lisa loves biotech but finds opera even more fun.

Dr. Waggett is the Programme Leader for IBM's Emerging Technology Group based at the Hursley Laboratory. He manages a team of 45 professionals and, in addition, performs consultancy assignments in support of a number of high profile projects for IBM. These projects include the UK's biometric matching system and the International Technology Alliance research programme into novel sensor networks. Dr Waggett has extensive experience of innovative IT systems, including research into image processing at University College London and the Marconi Research Centre. He has provided consultancy to a wide range of clients in the public and private sector including serving as an advisor to the UK Governments Chief Scientific Officer. His work includes responsibility for the delivery of innovative systems for a range of government and commercial organizations and he has been the Big Data subject matter expert for a range of projects and clients including the UK's biometric visa matching system.

Steve Jackson FRS, FMedSci is University of Cambridge Professor of Biology, Head of Cancer Research UK Laboratories at the Gurdon Institute, and Associate Faculty member at the Wellcome Trust Sanger Institute. Steve’s pioneering academic research has provided us with many of the key principles by which cells respond to and repair DNA damage. He identified many DNA-damage-response (DDR) proteins, established how they function, and helped define how their dysfunction yields cancer and other diseases. Steve has been elected to EMBO, the UK Academy of Medical Sciences and the Royal Society, and he has received various prizes, including most recently the Gagna and Van Heck Prize 2015, the King Faisal International Prize for Science 2016 and the Royal Netherlands Academy of Arts and Sciences Dr A.H. Heineken Prize for Medicine. Steve’s publications have collectively been cited >54,000 times (h-index 117; Google Scholar).

Recognizing that many DDR proteins represent attractive drug targets, in 1997 Steve founded and then scientifically led (he was part-time Chief Scientific Officer, 1997-2009) the company, KuDOS Pharmaceuticals, which was acquired by AstraZeneca in 2006. Four KuDOS compounds are now in clinical trials, the most advanced being the PARP inhibitor olaparib/LynparzaTM, which Steve and colleagues showed exhibits striking cytotoxicity towards cancer cells mutated in BRCA1 or BRCA2. Ensuing clinical studies with olaparib established a new cancer therapy paradigm, wherein a cancer cell’s genetic deficiency (such as loss of BRCA1 or BRCA2 function) is exploited pharmacologically through a mechanism termed “synthetic-lethality”, resulting in cancer cell killing with only mild effects on the patient’s normal cells. Olaparib/Lynparza recently received FDA and EMA approval for ovarian cancer with associated BRCA1/2 mutations and is now marketed in over 40 countries. Olaparib is also in late-phase clinical trials for various other cancers.

In 2010, Steve co-founded the company MISSION Therapeutics to exploit new therapeutic opportunities arising from his work on protein ubiquitylation and deubiquitylation. He currently serves as a director and part-time MISSION Chief Scientific Officer. While Steve’s academic laboratory has strong scientific links to MISSION, it is supported almost entirely by peer-reviewed grant funding.

Antony is the Regional Director for Europe at MINT. He has worked in the pharmaceutical industry since 1991, gaining experience from a wide range of territories including Asia, the US and the European Union. He worked for an equally diverse range of companies, including Schering Plough, MSD, BMS and Novartis before joining the Mundipharma network around six years ago as General Manager at Napp. Antony’s wide-ranging industry experience includes swine and poultry marketing, global marketing, new product planning and business development. Unexpectedly, before entering marketing Antony studied terrorism before it became quite so fashionable amongst academics. With four children and a hectic work schedule, Antony has precious little spare time, most of which is spent enjoying the Cambridgeshire countryside.

Tarquin is a Principal Consultant based from London covering EMEA and North America at Carmichael Fisher. He has over 18 years of executive search experience and specialises in C-Suite and senior leadership and NED appointments within biotech, diagnostics, biopharma, digital health, convergent technology and rare and orphan disease SMEs. He has recently been working in partnership with biotech, digital health and rare and orphan disease SMEs as they commercialise across Europe and North America.

Carmichael Fisher is an International Executive Search firm EMEA Headquartered in London with offices in Brussels, Frankfurt, Hamburg and Stockholm. Their market leading multilingual EMEA Life Sciences Practice conducts local and international cross-border assignments. Clients range from small local organisations to some of the largest brands and most highly respected international Life Sciences companies. Their services include: Executive Search, Market Analysis Projects, Competitor Intelligence, Talent Benchmarking and Executive Assessment.

Tarquin is a contributor to industry journals and has been invited to speak at international conferences on talent acquisition and management. He has been a lecturer on the prestigious Masters in Bioscience Enterprise programme on behalf of Cambridge University since 2008. Tarquin has a Bachelors Honours degree in English and Education from the University of Cambridge.

Active in the organisation of international conferences and networks including The Paperless Lab and The Innovation Forum.

Neil, along with Jonathan Cooper, co-founded george james ltd in 1999. Since this time Neil has successfully completed multiple recruitment projects across the life science, software and instrumentation industries. Projects cover Europe and range from senior field specialist to board level appointments. Neil is also involved in training, in particular one on one coaching programmes.

Prior to this Neil spent 16 years in various sales. marketing and general management positions working with Packard Biosciences, Perkin Elmer Applied Biosystems and MDS Sciex. Experienced in capital equipment, consumables, reagents and services in the life science, general analytical and process markets. At Packard Biosciences Neil was responsible for all European direct and distributor operations with revenues of >$100M and >150 employees. Neil has a degree in Medicinal Chemistry.

Ian is EY’s UK Biotechnology leader, and Executive Director in the audit practice, based in Reading, UK. Ian has over 20 years experience working with fast-growth innovative companies in the life sciences and technology sectors, both in Europe and the USA. Ian’s experience includes taking companies public in the US and UK, and accounting standards conversions between UK, International and US GAAPs. Ian is UK spokesman for EY’s annual Global Biotechnology Report “Beyond Borders”, which is now in its 30th year of publication.

Sarah Haywood became Chief Executive Officer of MedCity in December 2015, after fulfilling the role in an acting capacity and then as COO since MedCity’s launch in April 2014.

Sarah is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit, located on the UCL campus.

From there, Sarah joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners where she worked with Dr Eliot Forster to establish MedCity.

Sarah has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.

Linda has over 25 years in the global pharmaceutical industry in large pharmaceutical companies, small biotechnology companies, private equity ventures and specialist service providers. Her main areas of therapeutic expertise are oncology and respiratory. Linda worked for 18 years at AstraZeneca, where she held a variety of roles, including project director for Iressa to first registrations in Oncology, Accolate to NDA in asthma, and culminating in being Head of Strategy and Portfolio for the Oncology and Infection Therapy Area Management Team (TAMT). She was also SVP Portfolio and Project Integration (PPI) at Merck KGaA, based in Darmstadt, leading the portfolio steering committees for Oncology, Cardiovascular and CNS development programmes as well as managing a department of commercial and development staff. Subsequently, Linda was Partner at Celtic Pharma Holdings Advisors LLP, where she took responsibility for identifying assets for investment, conducting due diligence on these assets and ensuring all investee companies had solid clinical development plans in place. She also managed assets once acquired, including roles as Head of Clinical and Preclinical Development at Cantab Biopharmaceuticals, Interim CEO at Novacta Biosystems Ltd. and CEO at Dialog Devices Ltd. Latterly Linda became a Senior Partner at TranScrip, a specialist service provider to the pharma and biotech industry, where she leads oncology services and directly supports clients working in oncology. Immodulon is her major commitment for the foreseeable future, it is a UK-based biopharmaceutical company pioneering immunotherapies to transform the way that cancer is treated in the world today. Linda has a first degree and PhD from Cambridge UK, and held a NATO post-doctoral Fellowship tenured at University of California, San Francisco.

Paolo Moscuzza is a Chartered Psychologist, Associate Fellow of the British Psychological Society and a registered coaching Psychologist. He is a former winner of ‘HR Management Consultant of the Year’ as featured in the Sunday Times and his approach has been described as “fresh, energetic and innovative”.

Paolo has 20 years experience of assessing and developing the capability of leaders and he heads up OE Cam’s Leadership Development Practice. One of his specialist areas is identifying and leveraging disruptive talent to deliver innovation for business growth.

Karen is Director of Partnerships and Industry engagement for the Eastern Academic Health Science Network and the National Director for SBRI Healthcare.

As the NHS England national Director for SBRI Healthcare she leads a £20m investment programme where small enterprises are funded to develop technology solutions for healthcare problems. This award winning programme has over 150 companies under contract with the potential to impact 7m patients.

At Eastern AHSN she is supporting the Network to develop its role in economic development and wealth creation.

Formerly Director of NHS Midlands and East she supported the work of the regional health authority and the Public Health Team to promote closer working across all government. Karen led on relations with Local Government supporting the development of Health and Wellbeing Boards across the Midlands and East Cluster area.

A Board member of the East of England Development Agency (EEDA) Karen championed the work of the RDA in business development, communications, and equal opportunities. Karen was also board member of EEIDB, the service provider for Business link in the East of England. The Business Link service provided specialist business advice and support to start ups, SMEs and high growth companies across the region.

Before joining the team at the regional health authority Karen worked as a special adviser to the then Secretary of State for Health – Patricia Hewitt MP. With a specific remit to handle media and communications she also had responsibility for managing relationships with national stakeholders representing employer, patient and community interests.

Prior to her role in Westminster Karen was a campaigns and communications director for several national Trades Unions, the Labour Party and voluntary sector organisations.

Dr Kai Stoeber is Vice President of Global Innovation at Shionogi Europe and is an expert in cancer biology and biomarkers. Dr Stoeber received his M.Sc. in Biological Sciences from the University of Bonn and his Ph.D. from the University of Cambridge. His Ph.D. studies in the laboratory of Ron Laskey showed that dysregulation of the DNA replication initiation machinery is a major early event in the genesis of cancer, and led to a succession of translational spin-offs rooted in the basic biology of cell division. Insights into the mechanisms controlling DNA replication formed the basis for a range of promising diagnostic technologies developed in collaboration with biotech companies. From 2002-2014, Stoeber was co-principal investigator of the Chromosomal Replication Group at University College London. His work there with Gareth Williams led to a drug discovery programme focused on one of the kinases that jumpstart DNA replication initiation in partnership with CRUK’s own drug discovery lab, and resulted in the licensing of promising lead compounds to a major biopharma company for further development. A further spin-off from his research has been a novel cell cycle biomarker algorithm that identifies cell cycle kinetics in dynamic tumor cell populations and predicts response to cell-cycle phase-directed chemotherapeutic agents and selected targeted therapies. Dr Stoeber joined the Japanese pharmaceutical company Shionogi in 2014 where he identifies and evaluates transformative technologies as well as new targets or molecules from external sources in academia and biopharma. He remains an advocate of the importance of translational medicine in increasing the accuracy of early stage clinical development and reducing the risk of failure at later stages.

Neil spent a number of years rolling out mobile money platforms in emerging markets before working on a number of mobile health initiatives with the likes of Johnson & Johnson. In 2012, he started Skin Analytics with the goal of improving clinical outcomes for melanoma while reducing the cost of the disease to the public health system.

Neil holds a BSc in Mathematics and Physics from the University of Western Australia and an Executive MBA from London Business School

Giles is responsible Business Development and Project Management in the Diagnostics and Life Sciences market sectors at The Technology Partnership (TTP). In particular, Giles is driving TTP’s new Desktop Biology service for fast track conversion of assay to product. During 14 years with TTP, he has developed advanced analytical technologies including fluorescence-based systems, molecular diagnostics and electrochemical sensors, nanomechanical systems and microfluidics. Giles has also led the creation of a pharmaceutical consortium pioneering a innovative drug discovery technique and provided market entry analyses and scientific strategies for a range of major international corporations.

Giles has a degree in Chemistry and a DPhil in reactions at the solid-liquid interface under hydrodynamic conditions from Oxford University, funded through a scholarship from Glaxo. He was a member of the Editorial Board of the Journal of the Association of Laboratory Automation for a decade, is the co-author of an undergraduate textbook published by Oxford University Press and has over 20 publications and patents to his name. Prior to joining TTP, Giles worked for a biotechnology start-up company where he was responsible for their microfluidics and microfabrication developments.

Howard is a life science entrepreneur with an extensive network across pharma, biotech and University research through working for 24 years in industry and in the last 11 years with a portfolio career supporting innovation in Universities/Institutes and early stage companies. During 13 years at Genzyme, Howard contributed to therapeutic and diagnostic research, intellectual property and corporate development of tissue repair and molecular oncology businesses. Joining Cyclacel in 1998 with Executive responsibilities for research operations and business development over the 6 years when the company raised $100 million and put 2 products in the clinic.
More recently Howard has particular experience in building new companies to sustainability and growth, GT Biologics acquired into 4D pharma and for 5 years as Chairman of Symbiosis Pharmaceutical Services. Howard is currently Chairman of two companies, Neurocentrx a speciality Pharma Company building from initial products in pain and palliative care and Aquila Biomedical a preclinical CRO specialising in immuno-oncology drug discovery. He is also Entrepreneur in Residence to Sunergos Innovation and the Crick Institute.

Ilian is CEO and founder of EcoMachines Ventures. Prior to EcoMachines Ventures, Ilian founded and was CEO of CambridgeIP Ltd, a leading technology and IP strategy company. In that role, he led multiple technology and IP strategy engagements with corporate, SME and investor clients around the world in a range of sectors including energy, healthcare and telecoms. Before CambridgeIP, Ilian co-founded and ran a family business in the electrical industry in Southern Africa, focused on medium and high-voltage infrastructure.

Since 2001, Ilian has provided strategic advice to blue chip companies, high-growth technology companies and investors. Ilian’s research on the technology trends in energy and other sectors, and on innovation policy more broadly has been covered by major business media, including Harvard Business Review, Bloomberg, The Engineer and Renewable Energy Focus. He has worked with the likes of WIPO, IRENA, UNFCC and national governments on innovation finance and innovation policy. Ilian is also a regular speaker and has published widely in both academic and business media on the topics of innovation finance, science-industry technology transfer, service sector innovation and technology policy.
Ilian has a Master’s in Economics from Wits University (South Africa), and a PhD in innovation finance in emerging economies from the Judge Business School, Cambridge University.

Key publications include:
Who Owns Our Low Carbon Future? Intellectual property and energy technologies, Report co-authored with Chatham House (2009)
Barriers to Venture Capital Investment in Innovative SMEs in CEEs–Causes and Policy Implications , in Piech&Radosevic (eds) The Knowledge-Based Economy in Central and East European Countries , Palgrave MacMillan (2006)
FirstSolar : A Focus on the Technology Fundamentals - CambridgeIP Report (2011)
Desalination Technologies and the Use of Alternative Energies for Desalination – Report for International Renewables Energy Agency and World Intellectual Property Office (2012)
Membrane Filtration and UV Water Treatment: A report on selected water treatment technologies and their application in desalination systems - Report for World Intellectual Property Office (2012)
Desalination: new frontier for renewable energy? – Article for Renewable Energy Focus (2012)
Challenges and opportunities in the licensing of renewable technologies - Journal of Commercial Biotechnology (2009)
Role of Intellectual Property Rights in Technology Transfer - Report for UNFCCC (2008)
Intellectual Property: Crosslicensing, Patent Pools and Cooperative Standards as a Channel for Climate Change Technology Cooperation - Report for Climate Strategies (2008)

Jon Moore joined Horizon Discovery to manage its portfolio of target validation alliances in 2012 and became CSO in 2014. He leads a broad ranging internal research program that aims to deliver opportunities for spin out companies and also milestoned licensing deals. These have been focussed on synthetic lethal and immuno-oncology approaches to cancer, but are now shifting to encompass cell therapies. He is a Director of Avvinity Therapeutics, a joint venture between Horizon and Centauri Therapeutics that is exploring the potential of a novel ablative therapy for cancer. Prior to joining Horizon, Jon spent 10 years in drug discovery at Vernalis and prior to that he had extensive research experience in the laboratories of Sally Kornbluth and Nobel Prize winner, Tim Hunt.

Jim joined Sustainable Technology Investors Ltd (“STIL”) in 2011 after previously working in private equity and energy roles at Citi, PricewaterhouseCoopers and earlier in academia. He is a Chartered Financial Analyst and has a PhD in Physics from Imperial College. STIL manages investments in the renewable energy, energy efficiency, water and waste sectors. STIL manages family office capital, institutional funds, and high net worth investments through private equity funds. STIL focuses on the asset development of cash generative sustainable infrastructure, and on growth capital and venture capital investments.

Paul joined babylon in July 2016 and leads babylon’s work with the NHS.

Paul has been at the centre of policy and delivery on health for the last ten years, having worked at 10 Downing Street, the Cabinet Office and the Care Quality Commission as well as advising numerous NHS trusts, GP practices and commissioners.

Paul joins babylon from the Care Quality Commission, where he was a full Board Member and Executive Director of Strategy and Intelligence. He held national system roles including leading the Data and Outcomes domain of the Paperless 2020 programme. He was a member of the NHS Finance and Efficiency Board, New Models of Care Board and National Quality Improvement and Leadership Development group.

Prior to CQC, Paul worked at Downing Street for the Coalition Government, where he was the senior policy adviser on health and social care to both the Prime Minister and the Deputy Prime Minister. He also worked for the Prime Minister’s Delivery Unit under the last Labour government, where he led the health team and ran national reviews on cancer, elective waiting times, long term conditions and healthcare acquired infections.

Paul has a strong background in strategy, finances and organisational design, including working for consultants McKinsey & Company and as a director of 2020 Delivery. He achieved his doctorate in particle physics from the University of Manchester in 1999.

Dr Irvine leads the company’s strategic alliances with academic collaborators, key suppliers, and corporate partners. He has more than 25 years of experience in medical device product development including multiple regulatory approvals in USA, Europe, and Asia. Before joining Lightpoint, Dr. Irvine held senior R&D Director positions at CareFusion, Inverness Medical Innovations (now Alere), and Diomed (now AngioDynamics). He has 7 patents and is a Chartered Chemist of the Royal Society of Chemistry. Dr. Irvine holds a PhD and BSc in Chemistry from the University of Manchester.

Dr. Firat Yazicioglu is the head of Neuromodulation Devices at GSK Bioelectronics R&D and responsible for the development of implantable devices and creation of new technologies.

He has received his PhD degree from KU Leuven in Belgium and worked 13 years at imec, a Belgian technology research institute, where he has lead the research on biomedical circuits and systems for wearable and implantable applications. He has developed technologies for several biomedical devices including wireless cardiac monitoring patches, wearable EEG recording headsets, and implantable neural probes for high density recording of neural activity.

He has served in the technical program committees of European Solid State Circuits Conf (ESSCIRC), International Solid State Circuits Conf (ISSCC), and Biomedical Circuits and Systems Conf (BioCAS). He is still Assoc. Editor for IEEE Trans. of Biomedical Circuits and Systems.

John heads-up the Predictive Analytics practice in IMS Health’s Real-World Evidence Solutions. He develops innovative solutions to solve challenging healthcare problems using large-scale, real-world patient-level data based on a variety of advanced statistical and machine learning methods. This encompasses applications such as clinical decision-support tools, risk stratification calculators, rare disease detection algorithms and physician targeting alerts. John has over twenty years developing predictive analytics solutions in life sciences, financial services and academia. He is frequently invited to give thought leadership presentations in industry and academia. John received his PhD from Cambridge University and has held post-doctoral research positions at the University of Essex and the London School of Economics.

Prior to co-founding Medicxi Ventures, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He was formerly on the board of directors of Versartis (Nasdaq: VSAR) and is currently involved with include Acutus and Levicept among others.

Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals)and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.

Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD in Pathology from Cambridge University.

Mr. Foy joined SR One’s London office in 2011. Previously he was a Vice President at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York. Matthew studied Molecular Biology at The University of Oxford; Drug Discovery at UCL; Corporate Finance at The London Business School and holds various FSA & SEC qualifications. His portfolio companies include Asceneuron, Atopix, AtoxBio, Progenitor, PsiOxus, Puridify and VHSquared.

Raja Shankar is a Senior Principal with the IMS Consulting Group. He advises global pharmaceutical companies on commercial and patient access strategies; and governments and other policy stakeholders on policy reform related to better patient access to medicines. Raja is a thought leader on healthcare policy reform and change across Europe and other global markets. He has published and presented on pricing and patient access issues, especially how to both increase commercial success and effective access to medicine. These include presentations at Harvard, IMS PMA conferences, ISPOR and other external conferences in Europe, Asia and the US. He leads projects across therapeutic areas with a particular interest in upcoming innovations in oncology, cell and gene therapies, central nervous system diseases, auto-immune diseases, CV-metabolic diseases and vaccines. Raja also brings rich experience working across geographies—Europe, US and emerging markets in Asia, Latin America and Africa. He has a deep understanding of payer, policy and other healthcare stakeholders in these geographies. Prior to IMSCG, Raja worked with The World Bank and the Boston Consulting Group.

Mark has a long track record of business development for the group. With experience and a history of success in both sustainability and electronic component distribution he is an advocate of creating and exploiting new business opportunities with the aim of reducing carbon consumption and improving operational efficiency with the use of technology in the built environment through technology.

Since incorporation in 1982, APC Technology Group has developed out-standing relationships with manufacturers of specialist electronic components and with customers who put significant value on our deep understanding of the challenges of their individual markets, our technical expertise and our attention to detail.

Through both its electronic components division (Advanced Power Components), and its sustainability business (Minimise Energy Group), the business promotes a range of technologies developed to address the emerging ‘internet of things’ landscape, reduce energy consumption and carbon emissions. These products are either sold individually, or may be combined to provide an integrated, multi technology solution to the challenge of improving the energy efficiency of an entire organisation.

Mark is married with a daughter and has a passion for cycling, swimming and running.

Professor Piero Formica started his career as an economist at the OECD Economic Prospects Division in Paris, then moving to academic institutions. Professor Formica is Founder of the International Entrepreneurship Academy and was Professor of Economics with a special focus on innovation and entrepreneurship at the Jönköping International Business School in Sweden. He is currently a Senior Research Fellow of the Innovational Value Institute at the Maynooth University in Ireland where he leads an international research team on experimentation and simulation of high-expectation start-ups, and is the course leader of Experimental Entrepreneurship at the University Centre for Entrepreneurship, Design and Innovation. He is Adjunct Professor of Knowledge Economics, Innovation and Entrepreneurship at the Faculty of Entrepreneurship, University of Tehran (Iran), and a Guest Professor at the University of Tartu (Estonia) where he held the Marie Curie Professorship at the Faculty of Economics and Business Administration.

Professor Formica is a Councilor of the World Certificate Institute, a global certifying body that grants credential awards to individuals as well as accredits courses of organizations, and member of the International Advisory Panel of Amrita Center for Responsible Innovations and Sustainable Enterprises (ARISE), Amrita University, India.

Professor Formica received several awards and honors that include a Honorary Professor bestowed by the University of Mar del Plata (Argentina), a Guest Professor at King Saud University (Saudi Arabia) and at Curtin University of Technology, Curtin Business School (Perth, WA); a Special International Professor of Knowledge Economics and Entrepreneurship at Beijing University of Aeronautics and Astronautics (China); an International Professor of Knowledge Economics and Entrepreneurship at the Higher Colleges of Technology, United Arab Emirates; a Senior Research Fellow of the Enterprise Research and Development Centre Business School at the University of Central England in Birmingham; a Visiting Professor of Knowledge Economics and Entrepreneurship at the Jean Monnet Faculty of Political Studies (Second University of Naples, Italy); a member of the Advisory Council of the Institute for Enterprise and Innovation at the University of Nottingham, and a member of the Board of Governors of the University of Bologna, Italy, where he held the professorship of Economics of Innovation in the Masters of Business Law and Technology Management.

Professor Formica serves as board member of Industry & Higher Education; the International Journal of the Knowledge Economy; the International Journal of Social Ecology and Sustainable Development; the Journal of Global Entrepreneurship Research; the South Asian Journal of Management; and Frontiers in Education.

Professor Formica has extensively published in the fields of knowledge economics, entrepreneurship and innovation. THE EXPERIMENTAL NATURE OF NEW VENTURE CREATION. Capitalizing on Open Innovation 2.0, Springer, June 2013, has been co-edited with Professor Martin Curley (VP Intel Co.). Piero's most recent essays are: STORIES OF INNOVATION FOR THE MILLENNIAL GENERATION. The Lynceus Long View, Palgrave Macmillan, August 2013; THE ROLE OF CREATIVE IGNORANCE. Profile of Pathfinders and Path Creators, Macmillan Palgrave, December 2014; GRAND TRANSFORMATION TOWARDS AN ENTREPRENEURIAL ECONOMY. Exploring the Void, Emerald Group Publishing, December 2015. ENTREPRENEURIAL RENAISSANCE. Cities Striving Towards an Era of Renaissance and Revival is the forthcoming book of which Piero is the editor.

Simon specialises as a commercial contract lawyer for technology companies. He works for clients in the electronics, bioscience, defence, software and nanotech industries, advising companies ranging from small start-ups to big multinationals as well as individuals, public bodies and charities.

He advises on a wide range of contracts, including licenses, R&D collaborations, manufacturing agreements and procurement documentation. On the regulatory front he has advised on compliance with clinical trials legislation and novel food applications, as well as freedom of information and data protection issues.

Simon has co-written two business textbooks, Commercial Issues for Life Science Companies and Intellectual Property: the Lifeblood of your Company and has contributed articles to numerous publications, including the Financial Times, Patent World and Managing Intellectual Property. He regularly gives seminars and workshops at pharmaceutical conferences in the UK and internationally. He was also part of a UK IPO steering group putting together policies and contracts suitable for R&D collaborations in China.

Alan Kell is a renowned leader of world-class projects, consultancy and research programmes focused on delivering smart sustainable innovation in cities, communities and buildings.

He operates as a governmental advisor, programme director and international consultant, and has been actively supporting the development of international activities in this area since 1999.

For six years (2007-2012) he was the industry co-chair of the UK-China Eco-cities and Green Building Group, and he continues to development and promote Britain’s international business interests in these fields.

He is actively involved in the implementation of the UK’s Smart Cities Programme, and in the establishment of international relationships to capitalize this programme.

In October 2013 he organised and chaired UK Trade & Investment’s first international business event on Smart Cities, and in September 2014 established the Cambridge Cleantech Smart Cities Group which is leading the UK’s commercial implementation of smart city solutions. During 2014 he was appointment as an Independent Advisor to the UK All-Party Parliamentary Group on Smart Cities.

Since February 2015 he has been leading the project to establish the UK Smart Solutions Platform (SmartLink) to promote the UK’s commercial capabilities in this area.

In 2013 he was appointed as an Officer of the Excellent Order of the British Empire (OBE) by HM Queen Elizabeth the Second for his services to UK-China collaboration in the development and delivery of sustainable buildings and cities.

Harren Jhoti co-founded Astex in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. He also served as president and member of the Board of Directors of Astex Pharmaceuticals Inc., following the merger of Astex with SuperGen Inc., (subsequently renamed Astex Pharmaceuticals Inc.) in July 2011. Dr. Jhoti was elected a Fellow of the Royal Society of Chemistry in 2016 and of the Academy of Medical Sciences in 2015. He was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served on the board of the BIA, the UK BioIndustry Association and currently consults for Life Science Venture Capital firms. Before founding Astex in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.

Jack is the current editor of Naturejobs. He holds a Master’s degree in inorganic and materials chemistry, and has worked as a freelance writer, copyeditor and journalist for a variety of companies worldwide. He also has experience as a technical writer and project manager from time spent at a software development start-up.

Jack’s interests are in chemistry, scientific communications & journalism and career services. He’s enjoyed his time at Naturejobs and is proud of its impact on the job search for scientists across the world. He lives and works in London.

Steve is a founding management team member of Digital Science. As Director of Portfolio Development, he has overseen the growth of Digital Science's portfolio investments over the last 7 tears, mentoring startup founders from product and business model validation to launch and growth.

He closely manages the relationship between the portfolio companies and the corporate parent company, ensuring the right balance is struck between corporate oversight and freedom to innovate in a startup culture.
Separate to Digital Science's main investments (seed through to A- and B-rounds) he also manages the Catalyst Grant award, a twice-yearly award of up to £15k ($25k) to early stage ideas.

Prior to Digital Science, Steve setup and ran numerous startups in TV, video and publishing.

As a research scientist in the Oncology Research department at MedImmune, I am responsible for leading immuno-oncology projects at various stages of pre-clinical development. I also have a particular research focus on understanding the role of the myeloid cells in the tumour microenvironment in regulating anti-tumour immunity. Before joining MedImmune, I received my B.A. in Natural Sciences from the University of Cambridge, my Ph.D. in Neuroimmunology from the University of Manchester with Prof. Nancy Rothwell, and then performed post-doctoral research on the immune response to tissue injury with Dr. David Brough at the University of Manchester.

Mr. Edward Zheng, currently based in Singapore, founded Singapore Luxury Investment Group in October 2012.

Singapore Luxury Investment is a China-focused private equity and venture capital firm specialising in investments in growth capital, acquisition, mezzanine, PIPEs, mid-cap, leveraged buyouts, MBOs, capital increases, recapitalisation and capital and shareholding restructuring.

The firm seeks to invest in seed, middle market, mature, and later stage. It invests in sectors in Healthcare and Wellness Products and Services, Life Sciences, Telecommunication, Info-Comm, Internet and Information Technology, Pharmaceutical, Luxury Brands & Commercial Real Estate, Education and Hospitality/Tourism.

The firm targets investments globally with a focus on companies in China. It seeks to make cross border investments in mid-size European or Asian companies looking to leverage on a booming China economy as well as a partner for Chinese companies seeking a foothold in Europe and South East Asia. It also invests in OECD countries. It seeks to allocate around 60 per cent to China and 40 per cent to the rest of world.
The firm seeks to be an ethic of sustainable development, based on social and environmental responsibility criteria and currently manage a fund size of more than USD 2B.
Prior to his service in Singapore Luxury Investment Group, he was the investment director for Athena Hotel and Management based in Hong Kong. He had lead the investment for more than 40 projects in China and South East Asia in area of retail, tourism & hospitality & real estate.

Prior to his service in Athena Investment, he is the Country Manager for Greater China for British Telecommunication plc. A Fortune 500 company and one of the largest global providers in telecommunication products and managed services. Based in Shanghai, Edward had senior management responsibilities and sat on various advisory boards for companies in Asia Pacific.

Prior to his service in BT, he has served as Sales & Engineering Director for Keppel Communication, a Singapore government linked corporation, based out in Beijing. As an avid angel investor, he has invested and mentored more than 30 start-ups in China.

Prior to his service in Keppel, he has served as Project Manager for IBM Global Services, a Fortune 500 MNC in information technology and Software Programmer for Hewlett Packard Professional Services, another Fortune 500 MNC in information technology and software.

Edward Zheng is a highly sought after public speaker in area of social responsibilities, energy conservation, international trade, public policy in economic and social area, entrepreneurship, philanthropy, technology, venture capital, healthcare, urbanization and education.

He has made public speeches and received interviews in Shanghai, Beijing, Shenzhen, Guangzhou, Chongqing, Chengdu, Hangzhou, Nanjing, Nanning, Guilin, Zhengzhou, Wuhan, Xian, Guizhou, Changsha, Kunming, Yinchuan, Lanzhou, Qingdao, Suzhou, Hong Kong, Kuala Lumpur, Singapore, Sydney and Milan.

His most recent speech was Milano World Expo 2015 on 26 August 2015 on invitation of Ministry of Foreign Affairs of Italy where he spoke about the deep challenges and opportunities in agricultural industry in China.

Mr. Edward Zheng received a Bachelor of Mechanical Engineering degree with Honours from National University of Singapore. He has served as an Adjunct Professor in Guilin Aeronautical Technology University in 2009 - 2010.

Giles is the Head of Company Creation and joined Sunergos Innovations in 2014, prior to this he worked for Edinburgh BioQuarter. Both roles exposed him to the challenges of spinning out companies from a university setting. He has established companies across the healthcare sector from digital health, medical devices and drug development. A key to this success has been securing, both private and public funding to offset early stage risk. Also, by taking a hands-on approach to actively developing the investment opportunity, with the academic founders.

Highlights of his career include securing around £10m of non-dilutive funding to help develop early stage company formation opportunities, which led to around £50m of value creation for institutional stake holders. Spinning out 15 companies in the last four years.

Also, he has experience in commercial roles in the healthcare sector, including business development, licensing, new venture formation, product development and general management. Before coming to Edinburgh, he worked at Invitrogen and was a Business Enterprise Fellow at Oxford University & Isis Innovation Ltd. He has a Virology PhD from the University of Glasgow.

Lee has been operating within a dedicated energy team at Bouygues Energies and Services for the last 3 years. Working predominantly with public sector organisations and authorities, the multi award nominated team leads on providing energy performance contracting and infrastructure. As a corporation, innovation is a defining value for Bouygues, who invest £35 million each year into R & D. Lee’s own expertise helps drive both commercial and technical innovation; meeting the challenges of an ever changing market.

Lee’s also worked as a project manager for the Marshall Group, Land Systems Division, developing medical and disaster relief products for international markets. In 2011, he delivered the first project for Marshall to receive a Queens Award for Innovation.

Lee also provided services for Siemens SBS, on digitising the MOT system for VOSA, and for the NHS, phase one clinical trials at Sheffield Children’s Hospital.

Lee lives off grid in central Cambridge on houseboat Liberty, with his family. Passionate about the arts, he’s also a trustee of the Cambridge Art Salon.

Having originally trained as a surgeon and a corporate lawyer, Nicholas has over a decade and a half of experience in health sector with a broad range of leadership roles in industry, finance and policy as an advisor in Whitehall. Nicholas is a Chairman Emeritus of the Leadership Group, Member of the Council and an Honorary Treasurer of the New Technology in Medicine Section at the Royal Society of Medicine. He is also a Founding Fellow of the Faculty of Medical Leadership and Management. As well as being an investor, Nicholas is a frequent speaker, panelist and lecturer, including at the Stanford University Graduate School of Business and the Royal Society of Medicine where he co-founded one of the first Leadership and Management Master-classes for clinical leaders and helped to launch the first future clinical leaders network in the UK. His particular interests include corporate governance, ethics, corporate social responsibility and innovation in healthcare.

Nicholas holds undergraduate degrees in both Medicine and Law. He completed his medical training in London and specialised in Neurosurgery. He completed LL.B (Law) in London and postgraduate legal training in corporate law at the College of Law, where he graduated with Distinction. Nicholas also holds a Master’s Degree from the Imperial College and MBA from the London Business School with Coller Prize.

Philip is currently Commercial Director at PassivSystems, a privately-held company that deploys smart technology to create sustainable value in the residential energy market. He has a background in energy and cleantech, with over 12 years’ experience in business development, commercial strategy and marketing. Prior to working at PassivSystems he spent seven years at Bloomberg New Energy Finance and also worked at a venture capital firm investing in early-stage clean technologies. He has a degree in Modern Languages from Bristol University and an MBA from London Business School.

Chris started at Rolls-Royce but left to do a PhD in Physics followed by a Royal Society post doctoral research fellowship in Japan in the mid 1990s. As the mobile telecom industry expanded in the 1990s he joined a start-up developing basestation infrastructure equipment which was acquired by successively larger companies and where he stayed for nearly 10 years in a range of technical and marketing roles. He subsequently moved to be the VP for business development of a US based SME developing high speed microprocessor technology and moved to TTP in 2008. Since joining TTP Chris has worked on a range of projects often with a focus on energy efficiency or the energy sector more generally and, perhaps relevantly for this event, on an extended Carbon Trust funded project helping SMEs with low carbon technology get their products to market.